person

Federico R.

Country
Italy
Department
Medicina Sperimentale

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
84
Sites with multiple studies

Has run more than one trial at 84 of 194 partner sites.

Specializations

Neuromuscular Disorders

The investigator specializes in treating severe neuromuscular conditions, with particular focus on Duchenne Muscular Dystrophy and Generalized Myasthenia Gravis. Their research encompasses innovative therapeutic approaches for these challenging disorders.

  • Muscular Dystrophy Management
  • Myasthenia Gravis Treatment
  • Pediatric Neuromuscular Care

The investigator's work centers on evaluating novel therapeutic agents for neuromuscular conditions, particularly in pediatric and adolescent populations.

Therapeutic Innovation

Their clinical expertise extends to investigating exon-skipping treatments and advanced biological therapies. The research focuses on examining innovative drug delivery methods and therapeutic mechanisms for rare neuromuscular diseases.

  • Novel Drug Development
  • Intravenous Therapeutics
  • Treatment Safety Evaluation

The investigator evaluates pharmacokinetics and pharmacodynamics of new treatments for rare neuromuscular conditions.

Clinical Assessment

Expertise includes comprehensive evaluation of drug tolerability and protein level assessment in neuromuscular tissues. The investigator conducts detailed safety monitoring and efficacy measurements of experimental treatments.

  • Safety Protocol Development
  • Therapeutic Response Monitoring
  • Immunogenicity Assessment

Their work involves rigorous evaluation of treatment outcomes in neuromuscular disorders through multiple clinical parameters.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.